Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 5

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 5
---
 if your shares are held of record by a broker, bank, or other nominee and you wish to vote at the meeting, you must obtain from the record holder a proxy issued in your name.

If you own shares in street name through an account with a bank, broker or other nominee and you decide to attend the MIRA virtual annual meeting, you cannot vote at the MIRA virtual annual meeting unless you present a “legal proxy”, issued in your name from your bank, broker or other nominee.

THE MIRA BOARD HAS UNANIMOUSLY DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, MIRA AND ITS STOCKHOLDERS AND HAS UNANIMOUSLY APPROVED EACH SUCH PROPOSAL. THE MIRA BOARD UNANIMOUSLY RECOMMENDS THAT MIRA’S STOCKHOLDERS VOTE “FOR” EACH SUCH PROPOSAL.

| By Order of the MIRA Board of Directors, |
| /s/ Erez Aminov                          |
| Erez                                     
 Aminov                                   |
| Chief Executive Officer                  |
| Miami,                                   
 Florida                                  |

REFERENCES TO ADDITIONAL INFORMATION

This proxy statement incorporates information by reference that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission website, www.sec.gov, or upon your written or oral request by contacting MIRA Pharmaceuticals, Inc., Attention: Investor Relations, 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131, by calling (786) 432-9792.

To ensure timely delivery of these documents, any request should be made no later than September 1, 2025 to receive them before the MIRA virtual annual meeting.

For additional details about where you can find information about MIRA, please see the section titled “ Where You Can Find More Information” beginning on page 67 of this proxy statement.

<div align='center'>ABOUT THIS DOCUMENT</div>

MIRA Pharmaceuticals, Inc., which we refer to herein as the “Company,” “MIRA,” “we,” “our,” or “us” (unless otherwise indicated), is providing these proxy materials in connection with the solicitation by our board of directors of proxies to be voted at our Annual Meeting to be held exclusively online via live audio-only webcast on September 11, 2025, at 10:00 A.M. Eastern